Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

被引:15
|
作者
Zhou, Bin [1 ,2 ]
Shi, Yetan [3 ]
Fu, Rongrong [4 ]
Ni, Haixiang [5 ]
Gu, Lihu [1 ,2 ]
Si, Yuexiu [6 ]
Zhang, Mengting [3 ]
Jiang, Ke [3 ]
Shen, Jingyi [3 ]
Li, Xiangyuan [3 ]
Sun, Xing [1 ]
机构
[1] Univ Chinese Acad Sci, HwaMei Hosp, Dept Gen Surg, Ningbo, Peoples R China
[2] Univ Chinese Acad Sci, Ningbo Inst Life & Hlth Ind, Ningbo, Peoples R China
[3] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China
[4] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Peoples R China
[5] Zhejiang Chinese Med Univ, Dept Endocrinol, Affiliated Hosp 1, Hangzhou, Peoples R China
[6] Zhejiang Chinese Med Univ, Sch Basic Med Sci, Hangzhou, Peoples R China
来源
关键词
SGLT-2i; T2DM; ocular diseases; meta-analysis; RCTs; GLUCOSE COTRANSPORTER 2; INADEQUATE GLYCEMIC CONTROL; CHRONIC KIDNEY-DISEASE; LONG-TERM EFFICACY; DOUBLE-BLIND; JAPANESE PATIENTS; ADD-ON; SAFETY; EMPAGLIFLOZIN; PLACEBO;
D O I
10.3389/fendo.2022.907340
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: This meta-analysis was conducted to explore the association between sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and ocular diseases in type 2 diabetes mellitus (T2DM) patients. Methods: PubMed, Cochrane Central Registry of Controlled Trials, Web of Science and Springer were searched for articles on randomized controlled trials (RCTs) involving T2DM patients treated with SGLT-2i versus placebo or other hypoglycemic agents published prior to August 2021. The primary outcome of this meta-analysis was incidence of ocular diseases, which was assessed using risk ratios (RR) and 95% confidence intervals (CI). We reviewed 47 papers and compared the effect of SGLT-2i with the effect of the control groups (placebo and other hypoglycemic drugs) on the incidence of ocular diseases. Results: Compared with controls, overall SGLT-2i use in T2DM patients was not associated with incidences of cataract, glaucoma, retinal disease and vitreous disease. Ertugliflozin (RR=0.47, P=0.01) reduced the risk for retinal disease, while empagliflozin (RR=0.44, P=0.05) reduced the risk for diabetic retinopathy (DR) compared with controls. SGLT-2i (RR=0.50, P=0.02), perhaps empagliflozin (RR=0.47, P=0.06), reduced the risk of retinal disease compared with active hypoglycemic agents. Canagliflozin (RR=4.50, P=0.03) increased the risk for vitreous disease compared with placebo. Conclusions: There was no significant correlation between overall SGLT-2i and ocular diseases (cataract, glaucoma, retinal disease, vitreous disease, corneal disease, conjunctival disease, uveal disease, eye haemorrhage and vision problems) in T2DM patients. Ertugliflozin and empagliflozin may protect against ocular diseases, but canagliflozin may promote ocular diseases.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Shi, Nanjing
    Shi, Yetan
    Xu, Jingsi
    Si, Yuexiu
    Yang, Tong
    Zhang, Mengting
    Ng, Derry Minyao
    Li, Xiangyuan
    Xie, Fei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [2] Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
    Pan, Runzhou
    Zhang, Yan
    Wang, Rongrong
    Xu, Yao
    Ji, Hong
    Zhao, Yongcai
    [J]. PLOS ONE, 2022, 17 (12):
  • [3] Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
    Jiang, Yu
    Yang, Pingping
    Fu, Linghua
    Sun, Lizhe
    Shen, Wen
    Wu, Qinghua
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [4] Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Dimitrios Patoulias
    Alexandra Katsimardou
    Nikolaos Fragakis
    Christodoulos Papadopoulos
    Michael Doumas
    [J]. Acta Diabetologica, 2023, 60 : 1 - 8
  • [5] Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Patoulias, Dimitrios
    Katsimardou, Alexandra
    Fragakis, Nikolaos
    Papadopoulos, Christodoulos
    Doumas, Michael
    [J]. ACTA DIABETOLOGICA, 2023, 60 (01) : 1 - 8
  • [6] Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    Chaojie Feng
    Minxiang Wu
    Zhengyue Chen
    Xiongwei Yu
    Zhenyu Nie
    Yu Zhao
    Beiyan Bao
    [J]. International Urology and Nephrology, 2019, 51 : 655 - 669
  • [7] Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    Feng, Chaojie
    Wu, Minxiang
    Chen, Zhengyue
    Yu, Xiongwei
    Nie, Zhenyu
    Zhao, Yu
    Bao, Beiyan
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (04) : 655 - 669
  • [8] Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
    B-B. Qian
    Q. Chen
    L. Li
    C-F. Yan
    [J]. Osteoporosis International, 2020, 31 : 2313 - 2320
  • [9] Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
    Qian, B-B
    Chen, Q.
    Li, L.
    Yan, C-F
    [J]. OSTEOPOROSIS INTERNATIONAL, 2020, 31 (12) : 2313 - 2320
  • [10] Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials
    Shi, Yetan
    Si, Yuexiu
    Fu, Rongrong
    Zhang, Mengting
    Jiang, Ke
    Dai, Wei
    Shen, Jingyi
    Li, Xiangyuan
    Yuan, Yuan
    [J]. ENDOKRYNOLOGIA POLSKA, 2022, 73 (01) : 71 - 80